CSS
AMRX icon

Cubist Systematic Strategies’s Amneal Pharmaceuticals AMRX Stock Holding History

Cubist Systematic Strategies’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-684,116
Closed -$5.73M – 2926
2025
Q1 		$5.73M Buy
+684,116
New +$5.71M 0.03% 800
2024
Q2 		– Sell
-3,495
Closed -$21.2K – 2927
2024
Q1 		$21.2K Buy
+3,495
New +$19.7K ﹤0.01% 3470
2023
Q4 		– Sell
-241
Closed -$1.02K – 3544
2023
Q3 		$1.02K Buy
+241
New +$899 ﹤0.01% 3226
2023
Q2 		– Sell
-31,291
Closed -$43.5K – 3456
2023
Q1 		$43.5K Sell
31,291
-33,623
-52% -$66.9K ﹤0.01% 3586
2022
Q4 		$129K Sell
64,914
-69,490
-52% -$156K ﹤0.01% 3741
2022
Q3 		$271K Buy
134,404
+122,970
+1,075% +$345K ﹤0.01% 3578
2022
Q2 		$36K Sell
11,434
-4,396
-28% -$15.9K ﹤0.01% 4149
2022
Q1 		$66K Sell
15,830
-37,171
-70% -$165K ﹤0.01% 3325
2021
Q4 		$254K Sell
53,001
-37,537
-41% -$187K ﹤0.01% 2911
2021
Q3 		$483K Buy
90,538
+53,996
+148% +$272K 0.01% 2058
2021
Q2 		$187K Sell
36,542
-253,754
-87% -$1.44M ﹤0.01% 2587
2021
Q1 		$1.95M Buy
290,296
+241,886
+500% +$1.34M 0.03% 1054
2020
Q4 		$221K Sell
48,410
-49,484
-51% -$219K ﹤0.01% 2193
2020
Q3 		$380K Sell
97,894
-29,884
-23% -$128K 0.01% 1890
2020
Q2 		$608K Buy
127,778
+107,046
+516% +$441K 0.01% 1482
2020
Q1 		$72K Sell
20,732
-3,272
-14% -$13.9K ﹤0.01% 1961
2019
Q4 		$116K Sell
24,004
-40,394
-63% -$140K ﹤0.01% 2163
2019
Q3 		$187K Sell
64,398
-102,349
-61% -$357K ﹤0.01% 1800
2019
Q2 		$1.2M Buy
166,747
+152,249
+1,050% +$1.56M 0.02% 934
2019
Q1 		$205K Sell
14,498
-54,899
-79% -$726K 0.01% 1760
2018
Q4 		$939K Sell
69,397
-31,207
-31% -$562K 0.04% 589
2018
Q3 		$2.23M Buy
100,604
+58,891
+141% +$1.24M 0.12% 180
2018
Q2 		$685K Buy
+41,713
New +$732K 0.03% 648

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's AMRX Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of Amneal Pharmaceuticals (AMRX) in Q2 2025, closing a stake of 684,116 shares — an estimated $5.73M sold.

Cubist Systematic Strategies first reported a position in AMRX in Q2 2018 and held it in 23 quarters. The position peaked at $5.73M in Q1 2025. 241 funds tracked by Wall St. Rank hold AMRX as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining Amneal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 684,116 Amneal Pharmaceuticals shares in Q2 2025, an estimated $5.73M.
  • Cubist Systematic Strategies first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 23 quarters.
  • Cubist Systematic Strategies's Amneal Pharmaceuticals position peaked at $5.73M in Q1 2025.
  • 241 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.